表紙SALE
市場調查報告書
商品編碼
938713

新抗原癌症疫苗的全球市場:至2025年的預測與市場機會

Global Neoantigen Cancer Vaccine Market, By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2026

出版日期: | 出版商: TechSci Research | 英文 284 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

  • 全貌
  • 簡介
  • 目錄
簡介

全球新抗原癌症疫苗市場在預測期間內預計將以接近35%的年複合成長率成長。市場成長的主要原因,是技術迅速的創新和醫療部門的基礎建設的開發。

本報告提供全球新抗原癌症疫苗市場各市場區隔和各地區調查,市場規模及市場佔有率的預測,推動因素與課題,市場趨勢,競爭情形,企業簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 全球新抗原癌症疫苗市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各產品(個體化,市售)
    • 新抗原的各類型(核酸,樹突狀細胞,癌細胞,合成長肽(SLP))
    • 各給藥途徑(靜脈內,肌肉內,經皮,其他)
    • 各細胞(自我,同類)
    • 各技術(全基因序列,RNA序列,HLA型檢測)
    • 各傳遞機制(遺傳基因槍,電穿孔,微脂體,病毒體等)
    • 各用途(黑色素瘤,腦癌症,腸胃,肺等)
    • 各公司(2019)
    • 各地區
  • 市場魅力指數

第5章 亞太地區的新抗原癌症疫苗市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各產品
    • 各新抗原類型
    • 各給藥途徑
    • 各細胞
    • 各技術
    • 各用途
    • 各國
  • 市場魅力指數
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 澳洲

第6章 歐洲的新抗原癌症疫苗市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各產品
    • 各新抗原類型
    • 各給藥途徑
    • 各細胞
    • 各技術
    • 各用途
    • 各國
  • 市場魅力指數
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第7章 北美的新抗原癌症疫苗市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各產品
    • 各新抗原類型
    • 各給藥途徑
    • 各細胞
    • 各技術
    • 各用途
    • 各國
  • 市場魅力指數
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章 南美的新抗原癌症疫苗市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各產品
    • 各新抗原類型
    • 各給藥途徑
    • 各細胞
    • 各技術
    • 各用途
    • 各國
  • 市場魅力指數
  • 南美:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章 中東、非洲的新抗原癌症疫苗市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各產品
    • 各新抗原類型
    • 各給藥途徑
    • 各細胞
    • 各技術
    • 各用途
    • 各國
  • 市場魅力指數
  • 中東、非洲:國家分析
    • 南非
    • 沙烏地阿拉伯
    • UAE

第10章 市場動態

  • 促進因素
  • 課題

第11章 市場趨勢與發展

第12章 競爭情形

  • 競爭的展望
  • 主要企業的簡介
    • Avidea Technologies
    • Agenus
    • Roche
    • Nouscom
    • Merck
    • Pfizer
    • Advaxis
    • Medigene
    • Genocea Biosciences
    • Gritstone Oncology
    • Gilead Sciences
    • Eli Lilly
    • Novogene
    • Moderna
    • BioNTech
    • Ziopharm
    • ISA Pharmaceutical
    • Vaccibody
    • Brightpath Bio
    • Vaximm

第13章 策略性推薦事項

第14章 免責聲明

目錄
Product Code: 4566

Global neoantigen cancer vaccine market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD1754.44 million by 2026. The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to boost the growth of neoantigen cancer vaccine market across the globe in the coming years.

The global neoantigen cancer vaccine market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment is expected to dominate the market through 2026 and intramuscular is anticipated to be the fastest growing segment in the forecast period. This growth can be accredited to quick response as well as to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment in the coming years.

The application segment is further segregated into lung, melanoma, gastrointestinal, brain cancer, and others. The lung cancer segment is going to dominate the market in the forecast period as the neoantigen based immunotherapy of OSE Immunotherapeutics, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine is expected to launch in 2022. Tedopi (OSE2101), is used in the treatment of HLA-A2+ Lung cancer (NSCLC) patients. Currently, the vaccine is in phase III stage of clinical development.

Regionally, Asia Pacific neoantigen cancer vaccine market is expected to be the leading region over the forecast period due to the rising prevalence and incidence of cancer cases including lung cancer, melanoma, gastrointestinal, pancreatic cancer and other solid tumor indications.

Major players operating in the global neoantigen cancer vaccine market include OSE Immunotherapeutics SA, Gritstone bio, Inc., BioNTech SE, F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co., Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., Vaximm AG, Medigene AG, Genocea Biosciences Inc., Advaxis, Inc., Nouscom AG, among others are the leading players operating in global neoantigen cancer vaccine market. The companies operating in the market across the globe are focusing more towards expanding their share in the market.

Years considered for this report:

  • Base Year: 2020
  • Estimated Year: 2022
  • Forecast Period: 2023-2026

Objective of the Study:

  • To analyze and forecast the market size of global neoantigen cancer vaccine market.
  • To classify and forecast global neoantigen cancer vaccine market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution from 2021 to 2026 and growth rate until 2026.
  • To identify drivers and challenges for global neoantigen cancer vaccine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neoantigen cancer vaccine market.
  • To conduct pricing analysis for global neoantigen cancer vaccine market.
  • To identify and analyze the profile of leading players operating in global neoantigen cancer vaccine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the new products, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global neoantigen cancer vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Neoantigen cancer vaccine manufacturers and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to neoantigen cancer vaccine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global neoantigen cancer vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Neoantigen Cancer Vaccine Market, By Product:

  • Personalized neo-antigen vaccine
  • Off-the shelf neoantigen vaccine

Global Neoantigen Cancer Vaccine Market, By Neoantigen Type:

  • Synthetic Long Peptide
  • Nucleic acid
  • Dendritic cell
  • Tumor cell

Global Neoantigen Cancer Vaccine Market, By Route of Administration:

  • Intravenous
  • Intramuscular
  • Transdermal
  • Others

Global Neoantigen Cancer Vaccine Market, By Cell:

  • Autologous
  • Allogenic

Global Neoantigen Cancer Vaccine Market, By Technology:

  • RNA Sequencing
  • Whole Genome Sequencing
  • HLA Typing

Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:

  • Liposomes
  • Virosomes
  • Gene gun
  • Electroporation
  • Others

Global Neoantigen Cancer Vaccine Market, By Application:

  • Lung
  • Melanoma
  • Gastrointestinal
  • Brain cancer
  • Others

Global Neoantigen Cancer Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Singapore
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global neoantigen cancer vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Clinical Trial Analysis

4. Executive Summary

5. Global Neoantigen Cancer Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Personalized Neo-antigen Vaccine, Off-the Shelf Neoantigen Vaccine)
    • 5.2.2. By Neoantigen Type (Synthetic Long Peptide (SLP), Dendritic Cell, Nucleic Acid, Tumor Cell)
    • 5.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
    • 5.2.4. By Cell (Autologous, Allogenic)
    • 5.2.5. By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing)
    • 5.2.6. By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene gun and Others)
    • 5.2.7. By Application (Lung, Melanoma, Gastrointestinal, Brain cancer, and Others)
    • 5.2.8. By Company (2023)
    • 5.2.9. By Region
  • 5.3. Product Market Map

6. North America Neoantigen Cancer Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Neoantigen Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Cell
    • 6.2.5. By Technology
    • 6.2.6. By Application
    • 6.2.7. By Country
  • 6.3. Product Market Map
  • 6.4. North America: Country Analysis
    • 6.4.1. United States Neoantigen Cancer Vaccine Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Product
        • 6.4.1.2.2. By Neoantigen Type
        • 6.4.1.2.3. By Route of Administration
        • 6.4.1.2.4. By Cell
        • 6.4.1.2.5. By Technology
        • 6.4.1.2.6. By Application
    • 6.4.2. Canada Neoantigen Cancer Vaccine Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Product
        • 6.4.2.2.2. By Neoantigen Type
        • 6.4.2.2.3. By Route of Administration
        • 6.4.2.2.4. By Cell
        • 6.4.2.2.5. By Technology
        • 6.4.2.2.6. By Application
    • 6.4.3. Mexico Neoantigen Cancer Vaccine Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Product
        • 6.4.3.2.2. By Neoantigen Type
        • 6.4.3.2.3. By Route of Administration
        • 6.4.3.2.4. By Cell
        • 6.4.3.2.5. By Technology
        • 6.4.3.2.6. By Application

7. Europe Neoantigen Cancer Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Neoantigen Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Cell
    • 7.2.5. By Technology
    • 7.2.6. By Application
    • 7.2.7. By Country
  • 7.3. Product Market Map
  • 7.4. Europe: Country Analysis
    • 7.4.1. Germany Neoantigen Cancer Vaccine Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Product
        • 7.4.1.2.2. By Neoantigen Type
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Cell
        • 7.4.1.2.5. By Technology
        • 7.4.1.2.6. By Application
    • 7.4.2. France Neoantigen Cancer Vaccine Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Product
        • 7.4.2.2.2. By Neoantigen Type
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Cell
        • 7.4.2.2.5. By Technology
        • 7.4.2.2.6. By Application
    • 7.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Product
        • 7.4.3.2.2. By Neoantigen Type
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Cell
        • 7.4.3.2.5. By Technology
        • 7.4.3.2.6. By Application
    • 7.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Product
        • 7.4.4.2.2. By Neoantigen Type
        • 7.4.4.2.3. By Route of Administration
        • 7.4.4.2.4. By Cell
        • 7.4.4.2.5. By Technology
        • 7.4.4.2.6. By Application
    • 7.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Product
        • 7.4.5.2.2. By Neoantigen Type
        • 7.4.5.2.3. By Route of Administration
        • 7.4.5.2.4. By Cell
        • 7.4.5.2.5. By Technology
        • 7.4.5.2.6. By Application

8. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Neoantigen Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Cell
    • 8.2.5. By Technology
    • 8.2.6. By Application
    • 8.2.7. By Country
  • 8.3. Product Market Map
  • 8.4. Asia-Pacific: Country Analysis
    • 8.4.1. China Neoantigen Cancer Vaccine Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Product
        • 8.4.1.2.2. By Neoantigen Type
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Cell
        • 8.4.1.2.5. By Technology
        • 8.4.1.2.6. By Application
    • 8.4.2. India Neoantigen Cancer Vaccine Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Product
        • 8.4.2.2.2. By Neoantigen Type
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Cell
        • 8.4.2.2.5. By Technology
        • 8.4.2.2.6. By Application
    • 8.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Product
        • 8.4.3.2.2. By Neoantigen Type
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Cell
        • 8.4.3.2.5. By Technology
        • 8.4.3.2.6. By Application
    • 8.4.4. Australia Neoantigen Cancer Vaccine Market Outlook
      • 8.4.4.1. Market Size & Forecast
        • 8.4.4.1.1. By Value
      • 8.4.4.2. Market Share & Forecast
        • 8.4.4.2.1. By Product
        • 8.4.4.2.2. By Neoantigen Type
        • 8.4.4.2.3. By Route of Administration
        • 8.4.4.2.4. By Cell
        • 8.4.4.2.5. By Technology
        • 8.4.4.2.6. By Application
    • 8.4.5. South Korea Neoantigen Cancer Vaccine Market Outlook
      • 8.4.5.1. Market Size & Forecast
        • 8.4.5.1.1. By Value
      • 8.4.5.2. Market Share & Forecast
        • 8.4.5.2.1. By Product
        • 8.4.5.2.2. By Neoantigen Type
        • 8.4.5.2.3. By Route of Administration
        • 8.4.5.2.4. By Cell
        • 8.4.5.2.5. By Technology
        • 8.4.5.2.6. By Application
    • 8.4.6. Singapore Neoantigen Cancer Vaccine Market Outlook
      • 8.4.6.1. Market Size & Forecast
        • 8.4.6.1.1. By Value
      • 8.4.6.2. Market Share & Forecast
        • 8.4.6.2.1. By Product
        • 8.4.6.2.2. By Neoantigen Type
        • 8.4.6.2.3. By Route of Administration
        • 8.4.6.2.4. By Cell
        • 8.4.6.2.5. By Technology
        • 8.4.6.2.6. By Application

9. South America Neoantigen Cancer Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Neoantigen Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Cell
    • 9.2.5. By Technology
    • 9.2.6. By Application
    • 9.2.7. By Country
  • 9.3. Product Market Map
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Product
        • 9.4.1.2.2. By Neoantigen Type
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Cell
        • 9.4.1.2.5. By Technology
        • 9.4.1.2.6. By Application
    • 9.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Product
        • 9.4.2.2.2. By Neoantigen Type
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Cell
        • 9.4.2.2.5. By Technology
        • 9.4.2.2.6. By Application
    • 9.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Product
        • 9.4.3.2.2. By Neoantigen Type
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Cell
        • 9.4.3.2.5. By Technology
        • 9.4.3.2.6. By Application

10. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Neoantigen Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Cell
    • 10.2.5. By Technology
    • 10.2.6. By Application
    • 10.2.7. By Country
  • 10.3. Product Market Map
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Product
        • 10.4.1.2.2. By Neoantigen Type
        • 10.4.1.2.3. By Route of Administration
        • 10.4.1.2.4. By Cell
        • 10.4.1.2.5. By Technology
        • 10.4.1.2.6. By Application
    • 10.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Product
        • 10.4.2.2.2. By Neoantigen Type
        • 10.4.2.2.3. By Route of Administration
        • 10.4.2.2.4. By Cell
        • 10.4.2.2.5. By Technology
        • 10.4.2.2.6. By Application
    • 10.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Product
        • 10.4.3.2.2. By Neoantigen Type
        • 10.4.3.2.3. By Route of Administration
        • 10.4.3.2.4. By Cell
        • 10.4.3.2.5. By Technology
        • 10.4.3.2.6. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. OSE Immunotherapeutics SA
    • 13.2.2. Gritstone bio, Inc.
    • 13.2.3. BioNTech SE
    • 13.2.4. F. Hoffmann-La Roche Ltd.
    • 13.2.5. Pfizer Inc.
    • 13.2.6. Merck & Co. Inc.
    • 13.2.7. Moderna Inc.
    • 13.2.8. Avidea Technologies, Inc.
    • 13.2.9. Eli Lilly and Company
    • 13.2.10. Vaccibody AS
    • 13.2.11. Agenus Inc.
    • 13.2.12. Novogene Co., Ltd.
    • 13.2.13. ZIOPHARM Oncology Inc.
    • 13.2.14. ISA Pharmaceuticals B.V.
    • 13.2.15. BrightPath Biotherapeutics Co., Ltd.
    • 13.2.16. Vaximm AG
    • 13.2.17. Medigene AG
    • 13.2.18. Genocea Biosciences Inc.
    • 13.2.19. Advaxis, Inc.
    • 13.2.20. Nouscom AG

14. Strategic Recommendations

15. About Us & Disclaimer

List of Figures

  • Figure 1: Global Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
  • Figure 2: Percentage Change in Healthcare Spending (2020-2021), By Region
  • Figure 3: Global Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 4: Global Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 5: Global Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 6: Global Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 7: Global Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 8: Global Neoantigen Cancer Vaccine Market Share, By Delivery Mechanism, By Value, 2020-2026F
  • Figure 9: Global Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 10: Global Neoantigen Cancer Vaccine Market Share, By Company, By Value, 2023
  • Figure 11: Global Neoantigen Cancer Vaccine Market Share, By Region, By Value, 2020 & 2026F
  • Figure 12: Global Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
  • Figure 13: Global Neoantigen Cancer Vaccine Market Map, By Neoantigen Type, Market Size (USD Million) & Growth Rate (%)
  • Figure 14: Global Neoantigen Cancer Vaccine Market Map, By Application, Market Size (USD Million) & Growth Rate (%)
  • Figure 15: Global Neoantigen Cancer Vaccine Market Map, By Region, Market Size (USD Million) & Growth Rate (%)
  • Figure 16: North America Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
  • Figure 17: North America Health Spending Share, By Value, 2020
  • Figure 18: North America Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 19: North America Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 20: North America Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 21: North America Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 22: North America Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 23: North America Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 24: North America Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
  • Figure 25: North America Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
  • Figure 26: United States Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 27: New Cancer Cases Reported in the United States in 2020, Both Sexes, All Ages
  • Figure 28: United States Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 29: United States Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020 - 2026F
  • Figure 30: United States Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 31: United States Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 32: United States Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 33: United States Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 34: Canada Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 35: Canada Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 36: Canada Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 37: Canada Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 38: Canada Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 39: Canada Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 40: Canada Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 41: Mexico Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 42: Mexico Healthcare Spending, By Value, 2016 -2020 (USD Per Capita)
  • Figure 43: Mexico Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 44: Mexico Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 45: Mexico Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 46: Mexico Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 47: Mexico Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 48: Mexico Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 49: Europe Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
  • Figure 50: Leading Cancers in Europe, By Type, 2020
  • Figure 51: Europe Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 52: Europe Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 53: Europe Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 54: Europe Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 55: Europe Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 56: Europe Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 57: Europe Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
  • Figure 58: Europe Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
  • Figure 59: Germany Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 60: Germany New Cancer Cases, By Type, 2020
  • Figure 61: Germany Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 62: Germany Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 63: Germany Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 64: Germany Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 65: Germany Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 66: Germany Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 67: France Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 68: France Total Population, (In Million), 2016-2020
  • Figure 69: France Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 70: France Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 71: France Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 72: France Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 73: France Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 74: France Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 75: United Kingdom Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 76: Geriatric Population Numbers & Projections in United Kingdom (Millions), 2020
  • Figure 77: United Kingdom Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 78: United Kingdom Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 79: United Kingdom Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 80: United Kingdom Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 81: United Kingdom Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 82: United Kingdom Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 83: Italy Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 84: New Cancer Cases in Italy (%), Males, All Ages, 2020
  • Figure 85: Italy Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 86: Italy Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 87: Italy Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 88: Italy Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 89: Italy Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 90: Italy Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 91: Spain Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 92: New Cancer Cases in Spain (%), Females, All Ages, 2020
  • Figure 93: Spain Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 94: Spain Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 95: Spain Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 96: Spain Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 97: Spain Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 98: Spain Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 99: Asia Pacific Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
  • Figure 100: Number of New Cancer Cases in Asia Pacific (2020)
  • Figure 101: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 102: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 103: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 104: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 105: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 106: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 107: Asia Pacific Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
  • Figure 108: Asia Pacific Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
  • Figure 109: China Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 110: New Cancer Cases in China (%), 2020
  • Figure 111: China Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 112: China Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 113: China Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 114: China Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 115: China Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 116: China Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 117: India Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 118: Age Wise Prevalence of Breast Cancer in India, (%), Out of 100 Patients, 2020
  • Figure 119: India Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 120: India Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 121: India Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 122: India Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 123: India Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 124: India Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 125: Japan Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 126: Japan Total Health Expenditure as a share of GDP, 2016- 2020
  • Figure 127: Japan Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 128: Japan Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 129: Japan Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 130: Japan Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 131: Japan Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 132: Japan Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 133: Australia Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 134: % of Public and Private Hospitals in Australia, 2020
  • Figure 135: Australia Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 136: Australia Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 137: Australia Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 138: Australia Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 139: Australia Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 140: Australia Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 141: South Korea Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 142: New Cancer Cases in South Korea (%), 2020
  • Figure 143: South Korea Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 144: South Korea Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 145: South Korea Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 146: South Korea Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 147: South Korea Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 148: South Korea Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 149: Singapore Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 150: Singapore Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 151: Singapore Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 152: Singapore Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 153: Singapore Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 154: Singapore Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 155: Singapore Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 156: South America Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
  • Figure 157: South America New Cases of Cancer, By Type (%), 2020
  • Figure 158: South America Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 159: South America Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 160: South America Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 161: South America Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 162: South America Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 163: South America Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 164: South America Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
  • Figure 165: South America Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
  • Figure 166: Brazil Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 167: Brazil Healthcare Spending, By Value (USD Per Capita), 2016-2020
  • Figure 168: Brazil Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 169: Brazil Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 170: Brazil Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 171: Brazil Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 172: Brazil Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 173: Brazil Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 174: Argentina Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 175: Argentina Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 176: Argentina Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 177: Argentina Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 178: Argentina Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 179: Argentina Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 180: Argentina Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 181: Colombia Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 182: New Cancer Cases in Colombia (%), 2020
  • Figure 183: Colombia Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 184: Colombia Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 185: Colombia Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 186: Colombia Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F:

Figure 187 Colombia Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F

  • Figure 188: Colombia Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 189: Middle East and Africa Neoantigen Cancer Vaccine Market Size, By Volume (Million Units), By Value (USD Million), 2020-2026F
  • Figure 190: Middle East & Africa Geriatric Population Base (Age 60 & Above) % of Total Population, 2016-2020
  • Figure 191: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 192: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 193: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 194: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 195: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 196: Middle East & Africa Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 197: Middle East and Africa Neoantigen Cancer Vaccine Market Share, By Country, By Value, 2020-2026F
  • Figure 198: Middle East and Africa Neoantigen Cancer Vaccine Market Map, By Product, Market Size (USD Million) & Growth Rate (%)
  • Figure 199: South Africa Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 200: South Africa New Cancer Cases, By Type, 2020
  • Figure 201: South Africa Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 202: South Africa Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 203: South Africa Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 204: South Africa Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 205: South Africa Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 206: South Africa Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 207: Saudi Arabia Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 208: Saudi Arabia New Cancer Cases, By Type, 2020
  • Figure 209: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 210: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 211: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 212: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 213: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 214: Saudi Arabia Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 215: UAE Neoantigen Cancer Vaccine Market Size, By Value (USD Million), 2020-2026F
  • Figure 216: % of female population in UAE, 2016-2020
  • Figure 217: UAE Neoantigen Cancer Vaccine Market Share, By Product, By Value, 2020-2026F
  • Figure 218: UAE Neoantigen Cancer Vaccine Market Share, By Neoantigen Type, By Value, 2020-2026F
  • Figure 219: UAE Neoantigen Cancer Vaccine Market Share, By Route of Administration, By Value, 2020-2026F
  • Figure 220: UAE Neoantigen Cancer Vaccine Market Share, By Cell, By Value, 2020-2026F
  • Figure 221: UAE Neoantigen Cancer Vaccine Market Share, By Technology, By Value, 2020-2026F
  • Figure 222: UAE Neoantigen Cancer Vaccine Market Share, By Application, By Value, 2020-2026F
  • Figure 223: New Cancer Cases, By Type, 2020

List of Tables

  • Table 1: Canada Cancer Statistics, As of 2020
  • Table 2: Singapore Cancer Statistics, As of 2020
  • Table 3: Argentina Cancer Statistics, As of 2020